Standard BioTools Stock

Standard BioTools EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Standard BioTools (LAB) as of Jun 21, 2026 is -3.2.In the previous year, EV/EBIT (Enterprise Value to EBIT) was -6.83 — a change of -53.22% (higher).

EV/EBIT

-3.2

YoY

-53.22%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Standard BioTools is 2026 -3.2 . EV/EBIT (Enterprise Value to EBIT) of Standard BioTools was 2025 -6.83 . It decreases by -53.22% higher compared to the previous year.

The Standard BioTools EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2005
0 base
Jan 1, 2006
0 base
Jan 1, 2007
0 base
Jan 1, 2008
0 base
Jan 1, 2009
0 base
Jan 1, 2010
0 base
Jan 1, 2011
-1,502 base
Jan 1, 2012
-1,747 base
Jan 1, 2013
-5,610 base
Jan 1, 2014
-2,281 base
Jan 1, 2015
-554 base
Jan 1, 2016
-288 base
Jan 1, 2017
-333 base
Jan 1, 2018
-710 base
Jan 1, 2019
-448 base
YEARPRICE-TO-EBIT
2026 est -4,34
2025 est -3,95
2024 -4,59
2023 -2,78
2022 -0,79
2021 -4,40
2020 -8,47
2019 -4,48
2018 -7,10
2017 -3,33
2016 -2,88
2015 -5,54
2014 -22,81
2013 -56,10
2012 -17,47
2011 -15,02
2010 -
2009 -
2008 -
2007 -
2006 -
2005 -
Access this data via the Eulerpool API
Get Free API Key

Standard BioTools Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Standard BioTools's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Standard BioTools's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Standard BioTools's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Standard BioTools grows earnings faster than its peers.

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

EV/EBIT (Enterprise Value to EBIT) of Standard BioTools amounted to -6.83 -3.2

Access this data via the Eulerpool API
Get Free API Key

Valuation — Standard BioTools

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Standard BioTools